Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DYRK1A | Q13627 | 5/20 | 0.52 |
| ▸ | CLK1 | P49759 | 4/20 | 0.52 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.51 |
| ▸ | KIT | P10721 | 7/20 | 0.48 |
| ▸ | NEK1 | Q96PY6 | 1/20 | 0.46 |
| ▸ | ABL1 | P00519 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4829375 | 0.89 | DYRK1A (0.42) | DYRK1ACLK1NTRK1KITNEK1 | |
| SCHEMBL4827652 | 0.87 | NEK1 (0.45) | DYRK1ANTRK1KITNEK1ABL1 | |
| SCHEMBL4831106 | 0.86 | NTRK1 (0.46) | DYRK1ACLK1NTRK1KITNEK1 | |
| SCHEMBL4298090 | 0.85 | DYRK1A (0.53) | DYRK1ACLK1NTRK1KITNEK1 | |
| SCHEMBL4827380 | 0.85 | NTRK1 (0.50) | NTRK1KITNEK1 | |
| SCHEMBL4831294 | 0.85 | AXL (0.56) | DYRK1ANTRK1ABL1 | |
| SCHEMBL4832683 | 0.83 | MAPK1 (0.44) | DYRK1ACLK1NTRK1KIT | |
| SCHEMBL4829123 | 0.82 | NTRK1 (0.52) | DYRK1ACLK1NTRK1KIT | |
| SCHEMBL4823835 | 0.82 | MAP3K11 (0.47) | DYRK1ACLK1KITABL1 | |
| SCHEMBL4829477 | 0.82 | CDK2 (0.43) | DYRK1ANTRK1KITABL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| US-7446199-B2 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2008-11-04 | — | — | US | disclosed |
| EP-1664043-B1 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMA (US) | 2007-11-14 | — | — | EP | disclosed |
| US-20050137201-A1 | Compositions useful as inhibitors of protein kinases | VERTEX PHARMACEUTICALS INCORPORATED | 2005-06-23 | — | — | US | disclosed |
| WO-2005028475-A2 | COMPOSITIONS USEFUL AS INHIBITORS OF PROTEIN KINASES | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2005-03-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050137201-A1 | Compositions useful as inhibitors of protein kinases | MAP3K20, PACSIN2, MAP3K6 | DYRK1A 832/4885CLK1 444/4885NTRK1 1926/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.